NORTH AMERICA HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027
North America Hyperphosphatemia Drugs Market by Formulation (Calcium-based Phosphate Binders, Aluminum-based Phosphate Binders, Magnesium-based Phosphate Binders, Iron-based Phosphate Binders) & by Geography
The North America hyperphosphatemia drug market generated $xx million in 2018. The market is expected to grow at a CAGR of 15.19% and generate a revenue of $ million by the end of the forecast period for 2019-2027. Thus, the region would be holding the largest market share by the end of the forecast period as compared to the Asia-Pacific or Europe.
The countries analyzed for this region include the United States and Canada. The growing elderly citizenry, the changing dietary habits, and an increase in osteoporosis disease have acted as significant driving factors for this region. The market is segmented by the type of formulation which includes magnesium-based phosphate binders, calcium-based phosphate binders, aluminium-based phosphate binders, iron-based phosphate binders and others. The calcium-based phosphate binders are expected to dominate the market scene during the forecast years with a CAGR of xx%
Some of the prominent companies in the hyperphosphatemia drug market are Keryx, Amag, Royal Dsm, and Sun Pharma. Other players include Johnson and Johnson, Cipla, Zeria Pharmaceutical, Bruno Pharmaceutical Spa, Ultragenyx, Fresenius Medical Care, Pfizer Inc., Roche Diagnostics Corporation, R.H. Moore Drug Co, Sanofi, Vifor Pharma, Shire, and Fermenta Biotech Ltd.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- ESTIMATION METHODOLOGY
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- IRON-BASED HYPERPHOSPHATEMIA DRUGS IS A GAME CHANGER
- MARKET DETERMINANTS
- MARKET SCOPE & DEFINITION
- DRIVERS
- GROWING PREVALENCE OF CHRONIC DISEASES
- UNMET MEDICAL NEEDS
- SKEWED POPULATION MIX TOWARDS ELDERLY PEOPLE
- RISE IN PUBLIC AWARENESS
- RESTRAINTS
- LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION (FDA)
- GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
- CHALLENGES
- NON-ADHERENCE TO TREATMENT REGIMENS
- SIDE EFFECTS OF DRUGS
- LIMITED AVAILABILITY OF DRUGS
- USE OF ADVANCED DIALYSIS TECHNIQUES
- MARKET BY DOSAGE
- SOLID
- TABLET
- POWDER
- LIQUID
- SOLUTION
- SOLID
- MARKET BY FORMULATION
- CALCIUM-BASED PHOSPHATE BINDERS
- ALUMINUM-BASED PHOSPHATE BINDERS
- MAGNESIUM-BASED PHOSPHATE BINDERS
- IRON-BASED PHOSPHATE BINDERS
- OTHER PHOSPHATE BINDERS
- KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- BARGAINING POWER OF BUYERS
- BARGAINING POWER OF SUPPLIERS
- THREAT OF SUBSTITUTE PRODUCT
- INTENSITY OF COMPETITIVE RIVALRY
- OPPORTUNITY MATRIX
- KEY BUYING CRITERIA
- APPLICATION
- PRICING
- EFFECTIVENESS
- AVAILABILITY
- STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
- MARKET TRENDS
- PATIENT ASSISTANCE PROGRAMS
- STRATEGIC ALLIANCES
- INCREASE IN R&D
- PHOSPHATE BINDERS USAGES GUIDELINES
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHIC ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- NORTH AMERICA
- COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- COMPANY PROFILES
- AMAG PHARMACEUTICALS
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- BIOTECH PHARMACAL
- OVERVIEW
- PRODUCTS PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- BRUNO FARMACEUTICI SPA
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- CIPLA
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- FERMENTA BIOTECH LTD
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- FRESENIUS MEDICAL CARE
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- JOHNSON AND JOHNSON
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- KERYX BIOPHARMACEUTICALS INC
- OVERVIEW
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- PFIZER INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ROCHE DIAGNOSTICS CORPORATION
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ROYAL DSM N.V.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- SANOFI
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- SHIRE
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- SUN PHARMACEUTICAL INDUSTRIES LTD
- OVERVIEW
- PRODUCTS PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ULTRAGENYX PHARMACEUTICAL INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ZERIA PHARMACEUTICAL
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- AMAG PHARMACEUTICALS
TABLE LIST
TABLE 1 NORTH AMERICA HYPERPHOSPHATEMIA DRUG MARKET 2019-2027($ MILLION)
TABLE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017
TABLE 3 WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)
TABLE 4 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE 5 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027($ MILLION)
TABLE 6 NORTH AMERICA CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
TABLE 7 NORTH AMERICA ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
TABLE 8 NORTH AMERICA MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
TABLE 9 NORTH AMERICA IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
TABLE 10 NORTH AMERICA OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)
TABLE 11 PIPELINE PORTFOLIO OF HYPERPHOSPHATEMIA DRUGS
TABLE 12 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY COUNTRY 2019-2027($ MILLION)
FIGURE LIST
FIGURE 1 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE 2 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE
FIGURE 3 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
FIGURE 4 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
FIGURE 5 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
FIGURE 6 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2019-2027($ MILLION)
FIGURE 7 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2019-2027($ MILLION)
FIGURE 8 PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET
FIGURE 9 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET SHARE, 2019 & 2027 (%)
FIGURE 10 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)
FIGURE 11 THE UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)
FIGURE 12 CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027($ MILLION)
FIGURE 13 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)
- GEOGRAPHIC ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- MARKET SEGMENTATION
- MARKET BY FORMULATION 2019-2027
- CALCIUM-BASED PHOSPHATE BINDERS
- ALUMINUM-BASED PHOSPHATE BINDERS
- MAGNESIUM-BASED PHOSPHATE BINDERS
- IRON-BASED PHOSPHATE BINDERS
- OTHER PHOSPHATE BINDERS
- MARKET BY FORMULATION 2019-2027
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.